Covestor
AVBP icon

Covestor’s ArriVent BioPharma AVBP Stock Holding History

Covestor’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$0 Sell
8
-5
-38% -$153 ﹤0.01% 2911
2026
Q2 		$0 Buy
13
+4
+44% +$118 ﹤0.01% 2893
2026
Q1 		$0 Sell
9
-1
-10% -$23 ﹤0.01% 2848
2025
Q4 		$0 Sell
10
-1
-9% -$21 ﹤0.01% 2817
2025
Q3 		$0 Buy
11
+7
+175% +$138 ﹤0.01% 2862
2025
Q2 		$0 Hold
4
– – ﹤0.01% 2833
2025
Q1 		$0 Buy
+4
New +$98 ﹤0.01% 2804

Other funds holding AVBP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Covestor's AVBP Position: Q3 2026 in Review

Covestor reduced its ArriVent BioPharma (AVBP) stake by 38% in Q3 2026, selling an estimated $153 and leaving 8 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2911.

Covestor first reported a position in AVBP in Q1 2025 and has held it in 7 quarters since. 56 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Covestor held 8 shares of ArriVent BioPharma worth $0 as of Q3 2026.
  • Covestor sold 5 ArriVent BioPharma shares in Q3 2026, an estimated $153.
  • ArriVent BioPharma made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2911 holding.
  • Covestor first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 7 quarters since.
  • 56 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.